5-(ethylamino)-1-phenyl-1H-pyrazole-4-carboxylic acid | 1236148-80-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(ethylamino)-1-phenyl-1H-pyrazole-4-carboxylic acid
• 英文别名: 5-(ethylamino)-1-phenylpyrazole-4-carboxylic acid
• CAS: 1236148-80-3
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: HZLPFBAUDWTPMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Ethyl 5-(ethylamino)-1-phenylpyrazole-4-carboxylate 在 乙醇 、 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 5-(ethylamino)-1-phenyl-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  [EN] PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS
  [FR] DÉRIVÉS DE PYRAZOLE-1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DE SPHINGOSINE-1-PHOSPHATE

  摘要：

  公开的是Formula (I)或其药学上可接受的盐的化合物，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环烷基，每个可选地用从C1到C6烷基、C1到C4卤代烷基、苄基、OR4和/或卤素中独立选择的一个到五个取代基取代；R2、R3、R4和n在此处有定义。还公开了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，例如自身免疫疾病和血管疾病。

  公开号：

  WO2010085584A1

文献信息

• SUBSTITUTED PYRAZOLE COMPOUNDS
  申请人：Dyckman Alaric J.

  公开号：US20110275610A1

  公开（公告）日：2011-11-10

  Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R 1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C 1 to C 6 alkyl, C 1 to C 4 haloalkyl, benzyl, —OR 4 , and/or halogen; and R 2 , R 3 , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）化合物或其药学上可接受的盐，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环基，每个基团可选地被1至5个取自C1至C6烷基、C1至C4卤代烷基、苄基、—OR4和/或卤素的基团独立地取代；并且R2、R3、R4和n如本文所定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包括这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展，如自身免疫性疾病和血管疾病。
• Substituted pyrazole compounds
  申请人：Dyckman Alaric J.

  公开号：US08389509B2

  公开（公告）日：2013-03-05

  Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式(I)化合物或其药学上可接受的盐，其中：n为零或选自1至4的整数；R1为环烷基、芳基、杂芳基或杂环烷基，每个基团可选择地被一到五个取自C1至C6烷基、C1至C4卤代烷基、苯甲基、—OR4和/或卤素的基团独立地取代；R2、R3、R4和n的定义如本文所述。本发明还涉及使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在多种治疗领域中有用，例如自身免疫性疾病和血管疾病的治疗、预防或减缓疾病或障碍的进展。
• 5-Amino-pyrazoles as potent and selective p38α inhibitors
  作者：Jagabandhu Das、Robert V. Moquin、Alaric J. Dyckman、Tianle Li、Sidney Pitt、Rosemary Zhang、Ding Ren Shen、Kim W. McIntyre、Kathleen Gillooly、Arthur M. Doweyko、John A. Newitt、John S. Sack、Hongjian Zhang、Susan E. Kiefer、Kevin Kish、Murray McKinnon、Joel C. Barrish、John H. Dodd、Gary L. Schieven、Katerina Leftheris

  DOI：10.1016/j.bmcl.2010.10.034

  日期：2010.12

  The synthesis and structure-activity relationships (SAR) of p38 alpha MAP kinase inhibitors based on a 5-amino-pyrazole scaffold are described. These studies led to the identification of compound 2j as a potent and selective inhibitor of p38 alpha MAP kinase with excellent cellular potency toward the inhibition of TNF alpha production. Compound 2j was highly efficacious in vivo in inhibiting TNF alpha production in an acute murine model of TNF alpha production. X-ray co-crystallography of a 5-amino-pyrazole analog 2f bound to unphosphorylated p38 alpha is also disclosed. (C) 2010 Elsevier Ltd. All rights reserved.
• PYRAZOLE-I, 2, 4 -OXAD IAZOLE DERIVATIVES AS S.PHING0SINE-1-PH0SPHATE AGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2382211B1

  公开（公告）日：2012-12-19
• US8389509B2
  申请人：——

  公开号：US8389509B2

  公开（公告）日：2013-03-05